CN Patent

CN115298169B — (1r,3s)-3-(5-氰基-4-苯基-1,3-噻唑-2-基氨基甲酰基)环戊烷羧酸的共晶

Assigned to Palobiofarma SL · Expires 2024-11-19 · 1y expired

What this patent protects

本发明涉及(1R,3S)‑3‑(5‑氰基‑4‑苯基‑1,3‑噻唑‑2‑基氨基甲酰基)环戊烷羧酸的共晶、获得所述共晶的方法、包含所述共晶的组合产品和药物组合物及其医学用途，特别是用于治疗或预防已知通过A 1 腺苷受体拮抗作用而改善的疾病。

USPTO Abstract

本发明涉及(1R,3S)‑3‑(5‑氰基‑4‑苯基‑1,3‑噻唑‑2‑基氨基甲酰基)环戊烷羧酸的共晶、获得所述共晶的方法、包含所述共晶的组合产品和药物组合物及其医学用途，特别是用于治疗或预防已知通过A 1 腺苷受体拮抗作用而改善的疾病。

Drugs covered by this patent

Patent Metadata

Patent number
CN115298169B
Jurisdiction
CN
Classification
—
Expires
2024-11-19
Drug substance claim
No
Drug product claim
No
Assignee
Palobiofarma SL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.